Importance: The optimal treatment regimen for myopic choroidal neovascularization (mCNV) is essential to understand but currently poorly studied. Background: To date, there is still no consensus on the optimal dosage and frequency of anti-vascular endothelial growth factor injections in treating mCNV. Design: A prospective, single-centre, single-blind, randomized controlled study. Participants: Adult patients with active mCNV. Methods: Patients were randomized 1:1 to one or three doses initial ranibizumab treatments. Additional injections were administered pro re nata (prn) over 12 mo. Main Outcome Measures: Number and frequency of injections. Results: Fifty patients participated in the study. Patients in both 1 + prn or 3 + prn groups experienced similar best-corrected visual acuity gain and anatomical improvement, including central retinal thickness (CRT), CNV thickness, area of CNV and area of leakage. Over 12 mo, patients in the 1 + prn group received fewer ranibizumab injections (2.04 AE 1.22) compared with the 3 + prn group (3.58 AE 0.72, P<0.0001), but no statistic difference of the injection received was observed in the prn period. During the follow-up, 15 of 26 eyes in the 1 + prn group and 10 of 24 eyes in the 3 + prn group received additional injections after initial dosing (P = 0.2575). Cox regression analysis showed that 1 + prn, female, age > 55 y and CRT > 300 μm are risk factors for retreatment. Conclusions and Relevance: The eyes with a single loading dose achieved parallel anatomical and functional visual improvement, while required less injections over 1 y. The risk factors for retreatment include 1 + prn, female, older age and thick retina thickness.
the fundus, is one of the most frequent causes of visual impairment worldwide, especially in Asian populations. Myopic choroidal neovascularization (mCNV) is the most common complication of PM that threatens vision. It affects 5%-11% of the patients with PM and 0.04%-0.05% of the general population, and it is particularly prevalent among young and middle-aged Asians. 1, 2 Without treatment, there have been very poor outcomes for PM. Visual acuity may drop to 20/200 or less after 5 y and tends to a progressive enlargement with fibrotic evolution. 3, 4 Recently, it has been demonstrated that the vascular endothelial growth factor (VEGF) plays a specific role in the development of this disease. A therapeutic approach based on anti-VEGF reagents, namely ranibizumab, bevacizumab or aflibercept, becoming the first-line treatment for mCNV, has led to not only anatomical, but also functional improvements in patients. 5, 6 Long-term studies with at least 12 mo of follow-up showed 65%-92.7% of eyes with mCNV achieved visual improvement after anti-VEGF treatment. [7] [8] [9] [10] However, there is still no consensus on the optimal dosage and frequency of anti-VEGF injections to treat mCNV. The three initial monthly loading doses were used in several studies based on the experiences of treating CNV associated with wet age-related macular degeneration (wAMD). 11 Recently, one initial loading dose followed by pro re nata (prn) also proved to be effective. [12] [13] [14] The RADIANCE study proved that both the 1 + prn ranibizumab treatment guided by the disease activity and the 2 + prn ranibizumab treatment guided by the visual acuity stabilization were superior to photodynamic therapy (PDT), while no difference was observed between the two regimens. 13 A non-randomized prospective trial showed that the 1 + prn bevacizumab treatment could reach the same visual and anatomical outcomes with fewer injections but higher rate of retreatment compared with the 3 + prn bevacizumab treatment. 15 Kung et al also reported similar best-corrected visual acuity (BCVA) improvement between the 1 + prn and the 3 + prn ranibizumab group in a retrospective study. 8 To date, there is still no consensus on whether three consecutive monthly loading doses or one single initial dose should be used in treating mCNV. Therefore, we performed this prospective single-blind randomized clinical trial, SMILE study (Treatment and assessment Strategy for MyopIc CNV with LucEntis: A single-centre, prospective randomized controlled study) to evaluate and compare the 12-mo anatomical, functional outcomes, retreatment and recurrence rate of the two different initial regimens of intravitreal ranibizumab for mCNV treatment.
| METHODS

| Study design
The SMILE study was a prospective, single-centre, randomized, single-blind controlled study to compare the efficacy of the 3 + prn intravitreal ranibizumab treatment with the 1 + prn intravitreal ranibizumab treatment in patients with active mCNV. This study was approved by the Institutional Review Board of the Zhongshan Ophthalmic Center, Sun Yat-Sen University. All investigations followed the tenets of the Declaration of Helsinki. The study was registered on ClinicalTrials.gov (NCT0304287).
| Patients
A total of 54 patients with active mCNV were prospectively enrolled from March 2014 to July 2016. Fifty patients were followed up for 12 mo. The inclusion criteria were as follows: high myopia (spherical equivalence <−6.0D or axial length >26 mm) with active sub-foveal or juxtafoveal CNV confirmed by fundus fluorescein angiography (FFA) with hyperfluorescent CNV network on early frames and leakage of the dye on late frames, whose baseline BCVA from 24 to 73 Early Treatment Diabetic Retinopathy Study (ETDRS) letters. The exclusion criteria were as follows: the presence of other ocular diseases or evidence of any condition other than CNV associated with high myopia that affected the visual acuity, any anti-VEGF therapy performed within the last 6 mo, previous PDT, intraocular surgery performed within the last 3 mo, uncontrolled glaucoma, pregnancy or other severe systemic conditions, including uncontrolled systemic hypertension, and any history of thromboembolic or ischaemic cardiovascular disease.
| Randomization and treatment
Patients were randomized in a 1:1 ratio by random number generator to receive the 1 + prn or 3 + prn intravitreal ranibizumab treatments. In the 3 + prn group, patients received 3-monthly ranibizumab as loading doses; in the 1 + prn group, only single initial ranibizumab was injected at baseline. The additional treatment was administered based on the prn strategy, that is, if the mCNV persisted or recurred at a monthly visit, additional intravitreal ranibizumab treatment was administered. Retreatment was allowed in patients who met any of the following criteria, which is consistent with the MYRROR study: (a) reduction of BCVA >5 letters from the previous visit; (b) increase in central retinal thickness (CRT) >50um from the previous visit; new or persistent cystic retinal changes, subretinal fluid or pigment epithelial detachment; and (c) new or persistent bleeding or leakage in FFA or fundus examination. 14 Recurrence was defined as activation of CNV lesion if there has been at least a gap of 3 mo since the last anti-VEGF injection. A comprehensive ophthalmic examination, including BCVA, slit-lamp examination, intraocular pressure, fundus biomicroscopy, FFA and ocular coherence tomography (OCT), was performed at baseline. Fundus photography was performed with a Zeiss FF450 (Zeiss, Oberkochen, Germany). OCT was performed using Spectralis HRA (Heidelberg Engineering, Heidelberg, Germany) with enhanced depth imaging. All the patients were followed monthly for 1 y. Examinations at monthly follow-ups included BCVA, intraocular pressure, slit-lamp examination, fundus biomicroscopy and OCT. FFA was examined at baseline and at months 3, 6 and 12 in all patients. The investigators and image readers were blinded from the grouping information. The need for retreatment and the analysis of images was accessed in masked manner. The number of additional injection (retreatment) was calculated. The recurrence, which was defined as at least a gap of 3 mo since the last injection, was also investigated.
| Study outcomes
The primary outcome of this study was the total number of intravitreal injections in patients receiving the 1 + prn or 3 + prn ranibizumab treatment. The secondary efficacy endpoints were the mean BCVA, the changes of BCVA and the proportion of patients who gained ≥15 letters at month 12. Other outcomes included the following: CRT (defined as the distance between the vitreoretinal interface and the anterior surface of the retinal pigment epithelium [RPE] at fovea), CNV thickness (defined as the highest distance between the top of neovascular structure to the inner surface of RPE) and sub-foveal choroidal thickness (SFCT; defined as the distance from the bottom surface of RPE to the inner surface of sclera under the fovea) (see Figure S1 , Supporting Information) from baseline to months 3, 6 and 12 (all assessed by spectral domain-OCT); area of CNV (measured by circling manually the CNV's hyperfluorescence on early fluorescein angiography [FA] frames) and area of leakage (measured by circling manually the CNV's hyperfluorescence on late FA frames) from baseline to months 3, 6 and 12 in the 1 + prn and 3 + prn groups. OCT and FFA images were separately reviewed by two independent researchers (X.D. and S.L.). Any discrepancies in the data were resolved through reassessment and discussion with a senior researcher (L.L.). We also examined the total number of intravitreal injections, number of additional injections after initial dosing, the percentage of eyes requiring additional injection and the percentage of recurrent eyes in both groups. Systematic and ocular adverse events were assessed at each visit. Physical examinations, electrocardiograms, specialist consultation and laboratory tests were performed if necessary.
| Statistical analysis
The primary analysis population, which included the injection time, BCVA, anatomical outcomes and the retreatment and recurrence number, comprised the per-protocol (PP) population. The baseline characters and the Cox regression comprised the intention-to-treat population. The Cox regression analysis was stratified by both the treatment arm and other predictors to analyse the presence of first retreatment event. The safety analysis comprised the safety set population, which was defined as all randomized patients who received >1 study injection of ranibizumab. Based on the published results, the number of injections in 12 mo was reported as 2.32 (SD = 1.22) in the 1 + prn regimen and 3.57 (SD = 1.12) in the 3 + prn regimen in a retrospective study. 8 We used two-sided 95% confidence intervals to calculate the sample size. Under a 1:1 randomization ratio, a sample size of 48 patients was estimated to show a statistical significance with respect to the primary end point. By considering the dropout rate as 10%, 53 subjects were planned to be randomized and enrolled in this study. Analyses of continuous variables were performed by two-tailed Student's t test. Between-group comparisons for dichotomous end points were performed with Pearson's χ 2 test (or Fisher's exact test when appropriate). All statistical analyses were performed using Graph Pad Prism (GraphPad Software, CA, USA) or Stata 13.1 (StataCorp, College Station, TX, USA). The level of significance was set at P = 0.05.
| RESULTS
| Patient demographics and baseline characteristics
In total, 54 eyes from 54 consecutive patients were enrolled in this prospective study. Overall, 32/54 (59.3%) of the patients were female, and the mean age was 49.19 AE 14.22 y of age . The average spherical equivalent refractive error of all the eyes was −11.23 AE 3.60D, and the mean axial length was 28.59 AE 1.36 mm. A total of 27 of the patients were randomized to the 1 + prn group and received one ranibizumab injection as loading dose, and the other 27 patients received three initial injections as loading dose. Both groups had similar pre-treatment clinical and anatomical parameters. The mean age was 48.67 AE 14.20 y in the 1 + prn group and 49.70 AE 14.49 in the 3 + prn group (P = 0.79). The mean axial length was 28.67 AE 1.32 mm and 28.52 AE 1.42 mm (P = 0.67), and the average spherical equivalent refractive error was −11.88 AE 4.42 mm and -10.58 AE 2.94 mm (P = 0.23) for the 1 + prn and 3 + prn groups, respectively. In addition, there were no significant differences in baseline BCVA, CRT, CNV thickness, area of CNV and area of leakage in FFA between the two groups. The demographic and descriptive data are shown in Table 1 . All 54 eyes received the first injection, and thus, all 54 patients were included in the safety set based on the last observation carried forward approach. A total of 50 patients (26 in the 1 + prn group and 24 in the 3 + prn group) completed the 1-y follow-up, while three patients (one from 1 + prn and two from 3 + prn) were lost within the followup period and one patient from 3 + prn group was withdrawn due to the presence of rhegmatogenous retinal detachment (RRD) in the study eye.
| Treatment exposure
The average injection number over 12 mo was only 2.04 AE 1.22 in the 1 + prn group, while 3.58 AE 0.72 in the 3 + prn group, with a statistical difference of P<0.0001 (Figure 1 ). The median number of injections was 2 (range 1-6) in the 1 + prn group and 3 (range 3-5) in the 3 + prn group, respectively. Additional injection number after initial loading was 1.04 AE 0.24 in the 1 + prn group and 0.58 AE 0.15 in the 3 + prn group (P = 0.12).
| Visual acuity
BCVA improved rapidly after the initial loading phase. The most dramatic increase in BCVA happened after the first injection in both groups (Figure 2 ). The changes sustained and even slightly increased to month 12. During the followup, the mean BCVA improved from 54.4 AE 15.7 letters (baseline) to 64.6 AE 13.6 (month 3, P < 0.0001) and maintained at 67.5 AE 13.3 letters in month 12 (P < 0.0001) in the 1 + prn group (PP population). Similarly, in the 3 + prn group, the mean BCVA was from 49.4 AE 12.5 letters (baseline) to 63.3 AE 12.2 letters (month 3, P < 0.0001) and maintained at 65.8 AE 11.2 letters in month 12 (P < 0.0001) (PP population). In both groups, the mean BCVA during the follow-up was significantly increased when compared with the baseline. At month 12, the mean gain in BCVA was 
There was no statistically significant difference in BCVA, BCVA changes or proportion of patients gaining 15 letters or more at all measured time points between the two groups. Moreover, the majority of patients gained ≥5 letters in both groups, which was 80.8% (21/26) in the 1 + prn group vs 83.3% (20/24) in the 3 + prn group (P = 0.81). The proportion of patients losing 0-5 letters was 3.8% (1/26) in the 1 + prn group and 4.2% (1/24) in the 3 + prn group (P = 1.0). No patient in either group experienced vision loss of more than 5 letters (Table 2) .
| Anatomical outcomes
Our anatomical results showed an absence of leakage from CNV in 49 (98%) eyes at 12 mo. After 3 mo, 39 eyes showed no dye leakage in FFA, including 21 eyes in 1 + prn group and 18 eyes in 3 + prn group. At 12 mo, FA showed leakage in only one eye (2%) in 1 + prn group.
The mean CNV thickness statistically decreased in patients in both the 1 + prn group (183.33 AE 71.01 μm to 150.25 AE 66.67 μm, P = 0.006) and 3 + prn groups (187.73 AE 62.97 μm to 152.98 AE 60.80 μm, P = 0.015) in month 3, compared to the baseline. These changes were sustained and increased even more to month 12 (145.73 AE 67.53 μm in the 1 + prn group vs 152.76 AE 60.88 μm in the 3 + prn group). However, no statistical difference was observed between the 1 + prn group and 3 + prn group (Table 3, Figure 3 ). Although the baseline CRT in the 3 + prn group was numerically higher compared with that of the 1 + prn group without statistical significance (244.46 AE 84.61 in the 1 + prn group vs 262.92 AE 81.89 in the 3 + prn group; P = 0.44), after the 12-mo follow-up, the CRT decreased to a similar level in both groups (189.31 AE 57.74 in the 1 + prn group vs 197.58 AE 49.50 in the 3 + prn group).
In the 3 + prn group, the mean area of CNV decreased from 0.69 AE 0.53 mm 2 to 0.33 AE 0.30 mm 2 at month 12 (P = 0.006). The mean area of CNV also decreased from 0.66 AE 0.68 to 0.36 AE 0.49 in the 1 + prn group (P = 0.036). Similarly, no difference was observed between the two groups at each time point. In addition, the area of leakage was significantly reduced in both the 1 + prn and 3 + prn groups in months 3, 6, 9 and 12 compared with the baseline (P < 0.001). Still, no difference was observed between the two groups at each time point (Table 3 , Figure 4 ).
| Additional injections after initial dosing and recurrence rate
During the follow-up, 15/26 (57.7%) eyes received 27 additional injections in the 1 + prn group, while 10/24 (41.7%) eyes received 14 additional injections in the 3 + prn group, with no statistical difference (P = 0.2575). Notably, about half of the additional injections occurred during the first 4 mo. In the 1 + prn group, 16 out of 27 injections (59.3%) were given by month 4. Of the 26 patients, nine (34.6%), two (7.7%) and five (19.2%) patients were given additional injections on months 2, 3 and 4, respectively. In the 3 + prn group, six out of 14 (42.9%) injections were given in month 4. Additional injection was needed in six (23.1%) patients (eight injections) in 1 + prn group and five (20.8%) patients (six injections) in 3 + prn after month 5 (P = 1.0). In 1 + prn group, in total of 11 patients did not need any additional injection. In the 3 + prn group, 14 out of 24 patients did not need any additional injection (Tables 4 and 5, Figure 5 ). For 12 mo, seven of 26 patients in 1 + prn group experienced recurrence, while four of 24 patients in 3 + prn have recurrence over the entire follow-up (P = 0.38) (PP population).
| Risk factors for retreatment
Cox regression analysis was also performed to analyse the time until requiring retreatment as stratified by treatment regimen and various background characteristics. The results showed that the 1 + prn (3 + prn vs 1 + prn, hazard ratio [HR] = 0.38, P = 0.030), female (HR = 5.30, P = 0.013), age >55 y (HR = 3.57, P = 0.008) and CRT >300 μm (HR = 4.39, P = 0.010) are significant risk factors for retreatment (Table 6 ).
| Safety
At the 12-mo follow-up, one serious adverse event was reported in only one patient in the 3 + prn group. This patient had experienced RRD in the study eye at month 7. No systemic adverse events were found in any patients. No death was reported during the follow-up period. No ocular or systemic side effects related to intravitreal ranibizumab injections were observed.
The reduction of choroidal thickness was reported as a possible side effect of anti-VEGF treatment in both wAMD and diabetic macular oedema. 16, 17 In this study, we also mea- 7.96 AE 4.88 μm in 1 + prn group (not statistically significant from the baseline SFCT, P = 0.12) and 3.33 AE 2.74 μm in 3 + prn group (not statistically significant from the baseline SFCT, P = 0.24) at month 12.
| DISCUSSION
Myopic CNV is a major complication in patients with PM, which may cause subretinal haemorrhage, exudation, fibrosis and macular atrophy. It may finally lead to permanent visual loss or blindness if left untreated. 6 Recent data proved that anti-VEGF treatment could achieve significant visual improvement and decrease recurrence over long term, which opened a new era for mCNV treatment. 5, 18 However, there is still no agreement on the optimal therapeutic schedule of anti-VEGF treatment. Considered more mandated injections of loading doses in the 3 + prn regimen, it is not surprised that the total number of anti-VEGF injection was significantly higher compared with the 1 + prn regimen, which was consistent with the 3.57 injections in 3 + prn group vs 2.32 injections in 1 + prn group in previous study (P = 0.001). 8 Choosing one initial dosing means not only a more economical treatment cost, but also less potential risk of treatment. Kung et al retrospectively found there are no differences between the BCVA changes in 1 + prn and 3 + prn ranibizumab, while more retreatment was needed in 1 + prn group. In this article, 68% of the patients in the 1 + prn group needed additional treatment, while only 24% in the 3 + prn group needed additional treatment. 8 In another small sample prospective non-randomized study, 1 + prn and 3 + prn bevacizumab was suggested to have similar BCVA improvement, again, more recurrence rate was noted in 1 + prn group. 15 The 1 + prn treatment showed 15 recurrences vs four recurrences in the 3 + prn group, while the author did not mention the definition of recurrence. Thus, it is still a major concern whether one single injection is enough to suppress a mCNV lesion. However, so far, a randomized comparative prospective clinical trial is still lacking, especially for ranibizumab in Asians. To our knowledge, our current prospective study is the first prospective study on ranibizumab in mCNV.
In this randomized, controlled study, with relatively large sample size, we prospectively provided a high level of clinical trial evidence to confirm that 1 + prn intravitreal ranibizumab treatment could achieve parallel anatomical and functional visual outcomes over 12 mo compared with 3 + prn. Our results suggested that the 1 + prn strategy required fewer injections compared with the 3 + prn. However, both the number of patients needed the additional injection and the number of injections received in the prn period do not differ between these two groups.
It is well-documented that more injections imply more risk of endophthalmitis and a heavier economic burden. Our results confirmed that, with similar visual and anatomical outcomes, one initial dosage followed by prn ranibizumab could be safe and alleviate the social and economic burdens.
However, concerning the retreatment or recurrence rate in myopic CNV, the results remain controversial. In our study, within the 12-mo follow-up, the retreatment rate was 41.7% (10/24) in the 3 + prn group and 57.7% (15/26) in the 1 + prn group; 26.9% (7/26) patients in 1 + prn group experienced clinical recurrence, while 16.7% (4/24) patients The number of ranibizumab retreatments after the initial loading period in 1 + prn group and 3 + prn group in 3 + prn had recurrence over 12 mo. Although no statistical difference was observed probably due to the sample size, the Cox regression analysis showed that 1 + prn regimen was a significant risk factor for retreatment. However, the increased retreatment risk in 1 + prn group did not affect both the visual and anatomical outcomes at least in 1 y follow-up with significantly fewer injection.
In Ng et al's retrospective study, 28.6% in the 3-monthly loading group and only 18.8% in the single loading group required retreatment. 19 However, 68% patients in the 1 + prn vs 24% in the 3 + prn group were reported as receiving additional treatment in Kung et al's retrospective study. 8 Ruiz-Moreno et al found that 35% (7/20) in the 1 + prn group vs 21.1% (4/19) in the 3 + prn group needed additional injection in a non-randomized prospective study. 15 These disparities might be related to the study design. Patients in our prospective trial have monthly scheduled visit, while the follow-up visits were unscheduled in the retrospective study. mCNV patients with macular retinoschisis may need more injections to achieve visual gain. 20 Treatment responses could also vary between different ethnic groups. 21 In addition, retreatment/recurrence was defined differently in various studies. It should be noted that the retreatment and recurrence were quantified separately in this study. To our knowledge, this is the first prospective study to analyse clinical recurrence (defined as if there has been at least a gap of 3 mo since the last injection) in mCNV. The rate of retreatment needed could affect the clinical decision of regimen choice. Therefore, identifying risk factors is crucial to individualize the treatment strategy while minimizing the risk of over-treatment or under-treatment. In our study, Cox regression analysis was also used and showed that, among various baseline characteristics, 1 + prn (3 + prn vs 1 + prn, HR = 0.38, P = 0.030), female gender (HR = 5.30, P = 0.013), age >55 y (HR = 3.57, P = 0.008), CRT >300 μm (HR = 4.39, P = 0.010) were significant factors for recurrence or treatment failure.
To date, only very few retrospective studies have focused on the hazards of recurrence. Ng et al retrospectively studied 103 mCNV eyes with one initial loading injection of bevacizumab. Using multiple logistic regression analysis, they identified that large CNV size and long follow-up duration were significant predictive factors for retreatment. 19 Age could also be associated with the possibility of needing retreatment. In our study, the Cox regression analysis showed that the risk of retreatment in patients older than 55 y were 3.57 times higher than in younger patients. Similarly, a previous study showed that patients with CNV recurrence were, on average, 58.9 AE 17.1 y of age, while patients whose CNV did not recur were 48.7 AE 13.8 y of age (P = 0.004). 22 Our study also discovered that females are more susceptible to mCNV recurrence compared with males, whereas several retrospective studies failed to show any significant findings in this respect. Since mCNV always presents as classical CNV with little subretinal and intra-retinal fluid, the CNV thickness is difficult to measure precisely. Therefore, CRT are more comprehensive indicators used to correlate the thickness of the CNV itself and the disease activity, which could explain our results that CRT, but not CNV thickness, are significant hazards that indicate the need for retreatment. Therefore, an assessment of demographic characteristics and lesion features at the baseline could be critically helpful in choosing the appropriate treatment strategy. There are several limitations in our study. First, the baseline BCVA was lower in 3 + prn group than that in 1 + prn group, although not statistically different, which may have allowed the 3 + prn group to achieve a higher BCVA gain. A future trial with a larger sample size would be beneficial to determine the generalizability of these results. Second, patients in this study had exclusively Chinese ethnicity, which is one of the primary and most susceptible populations of mCNV patients. Since no existing epidemiological and clinical data show differences in prevalence and treatment effects between different geographic regions, it may be inferred that the results of this study are also relevant to patients with mCNV outside of China. Third, despite the promising results, patients were only followed up for 12 mo, and the long-term results remain unclear.
Conclusively, ranibizumab treatment, regardless of the initial treatment regimen, was effective in improving BCVA and several anatomical parameters in mCNV. Compared with the 1 + prn regimen, the number of total injections in 3 + prn regimen over 1-y period was significantly higher, which may increase the risk and cost of treatment. However, 3 + prn may decrease the risk of retreatment needed. Further studies with larger numbers of patients with long-term follow-up are necessary to establish the most appropriate dosing regimen and frequency and define the patient characteristics related to higher levels of recurrence in the future.
